answer text |
<p>Up to 50% of cancer patients enrolled in the 100,000 genomes project, including
patients with blood cancer, have seen a change in their treatment since receiving
their result. This could be eligibility for a new trial, or prescription of a new
medicine.</p><p>The National Genomic Test Directory outlines the range of genomic
tests – from whole genomic sequencing to tests for single genes and molecular markers
– that are available as part of the National Health Service clinical service.</p><p>From
summer 2019, whole genome sequencing will be implemented as part of routine clinical
care and be available to:</p><p>- Seriously ill children with a suspected genetic
disorder, including those with cancer;</p><p>- People with one of 21 rare and inherited
conditions; and</p><p>- People with specific types of cancer for which there is likely
to be the greatest patient benefit from using whole genome sequencing – children with
cancer, sarcoma and acute myeloid leukaemia.</p>
|
|